Non-adherence to community oral-antibiotic treatment in children with fast-breathing pneumonia in Malawi– secondary analysis of a prospective cohort study by Nightingale, R et al.
PneumoniaNightingale et al. Pneumonia  (2016) 8:21 DOI 10.1186/s41479-016-0024-8RESEARCH Open AccessNon-adherence to community
oral-antibiotic treatment in children
with fast-breathing pneumonia in
Malawi– secondary analysis of a
prospective cohort study
Rebecca Nightingale1, Tim Colbourn1, David Mukanga2, Limangeni Mankhambo3, Norman Lufesi4,
Eric D. McCollum5 and Carina King1*Abstract
Background: Despite significant progress, pneumonia is still the leading cause of infectious deaths in children
under five years of age. Poor adherence to antibiotics has been associated with treatment failure in World Health
Organisation (WHO) defined clinical pneumonia; therefore, improving adherence could improve outcomes in
children with fast-breathing pneumonia. We examined clinical factors that may affect adherence to oral antibiotics
in children in the community setting in Malawi.
Methods: We conducted a sub-analysis of a prospective cohort of children aged 2–59 months diagnosed by
community health workers (CHW) in rural Malawi with WHO fast-breathing pneumonia. Clinical factors identified
during CHW diagnosis were investigated using multivariate logistic regression for association with non-adherence,
including concurrent diagnoses and treatments. Adherence was measured at both 80% and 100% completion of
prescribed oral antibiotics.
Results: Eight hundred thirty-four children were included in our analysis, of which 9.5% and 20.0% were
non-adherent at 80% and 100% of treatment completion, respectively. A concurrent infectious diagnosis
(OR: 1.76, 95% CI: 0.84–2.96/OR: 1.81, 95% CI: 1.21–2.71) and an illness duration of >24 h prior to diagnosis
(OR: 2.14, 95% CI: 1.27–3.60/OR: 1.88, 95% CI: 1.29–2.73) had higher odds of non-adherence when measured
at both 80% and 100%. Older age was associated with lower odds of non-adherence when measured at 80%
(OR: 0.41, 95% CI: 0.21–0.78).
Conclusion: Non-adherence to oral antibiotics was not uncommon in this rural sub-Saharan African setting. As
multiple diagnoses by the CHW and longer illness were important factors, this provides an opportunity for further
investigation into targeted interventions and refinement of referral guidelines at the community level. Further
research into the behavioural drivers of non-adherence within this setting is needed.
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Pneumonia is the second leading cause of death among
children under five years of age and the leading cause of
death from an infectious disease, accounting for nearly
1 million deaths annually, with the greatest burden of
disease falling in Africa [1, 2]. The World Health Or-
ganisation (WHO) recommends the use of integrated
community case management (iCCM) at the commu-
nity health worker (CHW) level [3]. These guidelines
categorise pneumonia into non-severe pneumonia or
‘fast-breathing pneumonia’ (presence of a cough and/or
difficult breathing with a fast respiratory rate for age)
and advise treatment with oral antibiotics in the com-
munity, or severe pneumonia (presence of cough and/
or difficult breathing with chest in-drawing or danger
signs, irrespective of an increased respiratory rate for
age), which requires referral to a hospital [4]. Treatment
failure in those who have sought healthcare within the
community setting may contribute to the high mortality
rate from pneumonia in developing countries [5]. A
recent systematic review reported treatment failure
rates in fast-breathing pneumonia ranging between
7.8–22.9% [5], with a range of possible causes includ-
ing incorrect diagnosis, host comorbidities, concurrent
diagnoses, antibiotic resistance, and non-adherence to
oral antibiotics [6–8].
The development of tools to predict treatment failure
have tended to focus on clinical presentation; however,
with evidence demonstrating that non-adherence in-
creases treatment failure only [6], it stands to reason that
if adherence to oral antibiotics in community treated
pneumonia were improved, treatment failure rates could
be reduced. Therefore, approaches that aim to improve
adherence to oral antibiotics should be considered.
There are few studies that relate to short-term medica-
tion use in children that report a vast range of non-
adherence, from 3–60% [9–12]. To our knowledge,
there are no published articles with a primary outcome
of factors affecting adherence in children taking oral an-
tibiotics in sub-Saharan Africa. Several publications have
described different aspects of adherence related to
chronic conditions in sub-Saharan Africa and acute con-
ditions within the developed world. There is substantial
evidence that prescribing ‘patient friendly drugs’—for
example, reducing the duration of a course or number
of tablets per day—improved adherence [8, 13–17].
When treating children in sub-Saharan Africa diagnosed
with pneumonia, a three-day course of amoxicillin has
been shown to be as effective as a five-day course, and
improved adherence rates from 85% to 94% [18]. Other
factors that were shown to have some influence on ad-
herence included therapy-related reasons (such as taste
and texture) [11]; a patient’s relationship with the health
provider; access to healthcare; socioeconomic status; andcondition-related factors (e.g. how unwell the patient is)
[13, 19]. However, there is limited and conflicting evi-
dence surrounding all these factors, particularly in acute
conditions such as pneumonia, with a synthesis of sys-
tematic reviews finding over 770 separate factors in 51
systematic reviews of long-term treatments, yet found
no publication focusing on short-term treatments [13].
In light of this evidence gap, we aimed to investigate
clinical and diagnostic factors associated with non-
adherence to oral antibiotic treatment of fast-breathing
pneumonia in children at the community level, using
data from a prospective cohort in rural Malawi.
Method
This study is a sub-analysis of data collected during a
prospective cohort, between September 2013 and June
2014, of children treated with oral co-trimoxazole for
community-treated iCCM pneumonia in Mchinji District,
Malawi.
Data collection
The full methods of data collection have previously been
published [6]. Briefly, the study population comprised
all children aged 2–59 months diagnosed with fast-
breathing pneumonia by 34 government-employed
CHWs (called Health Surveillance Assistants) at their
village clinics in rural Mchinji and Lilongwe districts,
central region, Malawi. All children were dispensed oral
co-trimoxazole to take in the community. All eligible
participants who presented to CHWs and consented
were recruited. Data were collected from 18 clinics in
Mchinji and 16 in rural Lilongwe. Diagnoses and clin-
ical assessments, including pulse oximetry, were re-
corded by CHWs on case report forms. These forms
were barcoded, checked by supervisors, entered into a
database, and regularly cleaned throughout the project.
Lay village-level data collectors were recruited from the
local area and received one week’s training on the pro-
ject protocol and clinical measurements. They con-
ducted interviews at day 5 and day 14 in the home
setting, with day 0 being the day of diagnosis. When
subjects were not at home on day 5, re-visits were
made up to day 7. At these follow-up visits the data
collectors repeated a clinical examination for pneumo-
nia, visually confirmed reported antibiotic adherence
with pill counts, and asked about further care seeking
and treatments.
Definitions
Community treated iCCM pneumonia was defined as as
the observation or caregiver report of cough and/or diffi-
cult breathing and observed fast breathing (>50 breaths
per minute for infants 2–11 months; >40 breaths per mi-
nute for children 12–59 months), in the absence of any
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cluded vomiting everything, inability to feed, convulsions,
sleepiness or unconsciousness, and signs of severe respira-
tory distress including grunting, oxygen saturation <90%,
nasal flaring and head nodding. These were assessed based
on the caregivers report and clinical assessment by the vil-
lage data collectors or CHWs.
Non-adherence was measured using pill counts at the
day 5 visit. For the purpose of comparison we defined
non-adherence as both those who completed less than
80% (i.e. 7 or less of the 10 doses) and those who
completed less than 100% (i.e. missed any dose) of the
5-day, twice-daily course of co-trimoxazole. This regime
is the same as for amoxicillin and therefore the definition
of non-adherence can be applied as countries transition
from co-trimoxazole to amoxicillin. As per the standard
Malawi guidelines one dose is ½ tablet for 2–11 months
and 1 tablet 12–59 months.
Treatment failure was defined as the presence of any
of the following on the day after the final dose of antibi-
otics: fast breathing for age, axillary temperature >37.5 °C,
lower chest in-drawing, any danger sign, change of
antibiotic, hospital admission or death.
Analysis
Data were analysed using Stata version 13.1 statistical
software. We described non-adherence and conducted
multivariate analysis using logistic regression with 80%
and 100% adherence as the outcome variables in separ-
ate models. Based on the literature and prior know-
ledge, we included clinical presentation and concurrent
diagnoses and treatments in the multivariate model.
Clinical presentation was included using the following
variables: temperature (normal: <=37.4 °C, fever: > 37.4 °C);
oxygen saturation (normal = > 95%, abnormal <95%); age-
adjusted respiratory rate as breaths per minute (fast: 40–59
[age 12–59 months] 50–69 [age 2–11 months], very fast:
> = 60 [age 12–59 months] > =70 [age 2–11 months]);
and heart rate as beats per minute (normal: <159 [age
2–11 months] <149 [age 12–23 months] <139 [age
24–59 months]). Concurrent diagnoses at presentation
included: presumptive malaria (not laboratory or rapid
diagnostic test confirmed), diarrhoea; ear infection,
rash and other specified infection. Concurrent medica-
tions included: Paracetamol, Lumefantrine Artemether
(LA) and others specified (including aspirin, topical
creams, oral salbutamol). Duration of illness prior to
seeking care (caregiver reported as over 24 h or under
24 h), child vomiting after antibiotics, age (2–12
months, 1–2 years and 2–5 years) and gender were
also included.
To determine the inclusion of individual or composite
formulations of medication and concurrent diagnosis
variables, we looked at the correlation between theseindividual and composite variables; variables that had a
correlation of above 0.7 were not included in the same
model [21]. This resulted in the composite diagnosis/
medication variables being analysed separately from the
individual diagnosis and medication variables. The over-
all percentage of missing data was low, with all variables
having less than 5% missing data, and overall 12% of
records with any missing data. A complete case analysis
approach was taken.
Results
A total of 974 cases were presented for analysis. Of
these, 23 did not meet the criteria of fast-breathing
pneumonia (had no cough or difficulty breathing), and
117 were not at home on day 5 when the pill count was
completed. These patients were not included for ana-
lysis, which resulted in a total of 834 cases being
analysed.
Table 1 summarises the baseline characteristics of the
sample population and description of the clinical vari-
ables. Previously published baseline variables show those
lost to follow up had lower rates of malnutrition but also
lower rates of uptake of the PCV vaccination [6]. The
percentage of children diagnosed with another condition
concurrently to pneumonia was high (50.7%). Malaria
was the most common concurrent diagnosis, occur-
ring in 41.4% of children, and 61.8% of children
received any medication in addition to oral co-
trimoxazole. Caregiver histories revealed that 58% of chil-
dren were brought to the clinic for assessment on the day
they became unwell or within 24 h of illness onset. Just
over 12% of children vomited after taking any dose of co-
trimoxazole.
Non-adherence to oral co-trimoxazole was 9.5% when
measured at 80%, and 20.0% at 100% completion.
Treatment failure at day 5 was 14.9%, and 7.0% at day
14. While our aim was not to investigate treatment fail-
ure, the percentage of children failing treatment was
slightly higher in those that were non-adherent (19.0%;
95% CI: 16.3–22.0) versus adherent (14.4%; 95% CI:
12.0–17.1); however, this study was not powered to look
at this association. The results of the multivariate model
are presented in Table 2 (bivariate analysis is available in
the Appendix). For non-adherence measured at both 80%
and 100%, children with any concurrent diagnosis had
higher odds of being non-adherent to medication (OR:
1.76, 95% CI: 1.00–3.07/OR: 1.81 95% CI: 1.21–2.71,
respectively). In the multivariate model, concurrent mal-
aria diagnosis alone was not significantly associated with
non-adherence (OR: 1.20; 95% CI: 0.67–2.15/OR: 1.41
95% CI: 0.93–2.17). Children who were unwell for more
than 24 h before CHW diagnosis had significantly in-
creased odds of non-adherence at 80% and 100% (OR:
2.14, 95% CI: 1.27–3.58/OR: 1.88, 95% CI: 1.29–2.73).
Table 1 Characteristics and description of the study population
N = 834
N (%)
Age 2–11 months 268 (32.1%)
12–23 months 273 (32.7%)
24–59 months 293 (35.1%)
Gender Female 429 (51.4%)
Male 391 (46.9%)
Missing 14 (1.7%)
District Kabudula 479 (57.4%)
Mchinji 355 (42.6%)
Clinical malaria diagnosis Yes 345 (41.4%)
No 489 (58.6%)
Diarrhoea diagnosis Yes 28 (3.4%)
No 806 (96.6%)
Any concurrent diagnosisa Yes 423 (50.7%)
No 411 (49.3%)
Prescribed LAb Yes 430 (51.6%)
No 404 (48.4%)
Prescribed paracetamol Yes 430 (51.6%)
No 404 (48.4%)
Prescribed multiple drugs Yes 515 (38.2%)
No 319 (38.3%)
Duration of illness before diagnosis <24 h 482 (58.1%)
>24 h 347 (41.9%)
Vomited after taking antibiotics Yes 726 (12.7%)
No 106 (87.3%)
Number Medianc (range)
Respiratory rate (breaths/min) Age 2–11 mths 253 55 (40–83)
Age 12–59 mths 545 46 (40–100)
Temperature (°C) 803 42.0 (34.3–42)
Oxygen Saturation (%) 826 97 (90–100)
Number Meanc (SD)
Heart rate (beats/min) Age 2–11 mths 260 136 (24.7)
Age 12–23 mths 260 138 (24.9)
Age 24–59 mths 279 129 (23.2)
LA lumefantrine artemether, SD standard deviation
aDiagnoses included: malaria, diarrhoea, ear infection, rash and other specified
bThe child was presumptively prescribed the anti-malaria Lumefantrine Artemether (LA) by the community health worker
cMedian used for skewed data, mean for normally distributed data
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odds of <80% adherence (OR: 0.41, 95% CI: 0.21–0.78),
but this was not the case for <100% adherence. Chil-
dren prescribed multiple medications showed increased
odds of non-adherence in bivariate analysis, but not in
the adjusted analysis. The clinical severity of the child’s
pneumonia at diagnosis did not show a significantrelationship with non-adherence, nor did a child vomit-
ing after their antibiotics.
Discussion
We sought to describe the effect of clinical presentation
on adherence to oral antibiotics in children diagnosed
with community-treated iCCM pneumonia in rural Malawi.
Table 2 Multivariable regression for clinical and diagnostic factors associated with non- adherence
Adherence measured at 80% Adherence measured at 100%
Variable Odds Ratio P Value CI Odds ratio P Value CI
Any Concurrent Diagnosisa 1.75 0.050 1.00–3.07 1.81 0.004 1.21–2.71
Prescribed multiple drugsb 1.57 0.159 0.84–2.96 1.09 0.711 0.70–1.68
Duration of illness > 24 h 2.14 0.004 1.27–3.58 1.88 0.001 1.29–2.73
Abnormal oxygen saturationc 0.82 0.606 0.39–1.73 1.44 0.148 0.88–2.36
Very fast breathingd 0.82 0.754 0.22–2.92 0.66 0.355 0.27–1.60
Abnormal heart ratee 0.80 0.419 0.41–1.45 1.41 0.123 0.91–2.17
Feverf 1.50 0.150 0.86–2.60 1.06 0.777 0.70–1.61
Vomited antibiotics 0.82 0.605 0.38–1.77 0.85 0.574 0.48–1.50
Age (12–23months) 0.68 0.206 0.38–1.23 1.05 0.822 0.67–1.65
Age (24–56 month) 0.41 0.007 0.21–0.78 0.68 0.111 0.43–1.09
Sex (Male) 0.91 0.740 0.54–1.51 1.06 0.750 0.73–1.54
Pseudo R2 = 0.061 Pseudo R2 = 0.045
aDiagnoses included: malaria, diarrhoea, ear infection, rash and other specified
bDrugs included: Paracetamol, Lumefantrine Artemether (LA) and others specified (including aspirin, topical creams, oral salbutamol)
cNormal: = > 95%; Abnormal: <= 94%
dFast breathing (breaths per minute): 40–59 (age 12–59 months) 50–69 (age 2–11 months); Very fast breathing: > = 60 (age 12–59 months) > =70 (age 2–11 months)
eNormal (beat per minute): <159 (age 2-11months), <149 (age 12–23 months), <139 (age 24–59 months); Abnormal: > = 159 (age 2-11months), > = 149 (age 12–23
months), > = 139 (age 24–59 months)
fNormal: <=37.4 °C; Fever: > 37.4 °C
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adherence to oral antibiotics within these communities,
with 20% of children not finishing their full course of an-
tibiotics and nearly 10% not completing 80% of the
course. There is limited data to compare this to, with
available literature reporting a vast range of non-
adherence from 3–60% [9–12]. Having a secondary
diagnosis and presenting for treatment having been
unwell for more than 24 h before diagnosis were as-
sociated with non-adherence amongst this population.
Clinical severity
The limited literature available suggests that the more ser-
iously sick a child is, the more likely they are to be adherent
to medication [22]; however, our results did not find sever-
ity to be a main driver of adherence in this group. It is
plausible that the way this study has measured clinical pres-
entation is not how a caregiver would assess it, since mea-
sures such as oxygen saturation are non-visible whereas a
fever or faster respiratory rate may be visible to a caregiver.
As these children were being treated in the community,
caregivers may not have perceived them as seriously unwell.
This is supported by the fact that they were seeking care in
the community. However, with no studies reviewing chil-
dren with pneumonia in an African setting, it is possible
that the different cultural and local health beliefs mean se-
verity and risk are viewed differently, giving alternative re-
sults. Evidence suggests that in Malawi, especially in areas
with endemic tropical disease, health beliefs vary greatly
from Western models, particularly when understanding therisk of disease [23]. There is also potential that parents did
not see a benefit in continuing to give their child medica-
tion if the child (potentially with viral infections) improved
or, alternatively, caregivers saw no to minimal improvement
after completing 3 or 4 days of treatment. Research aiming
to predict pneumonia treatment failure in Malawi showed
limited success in using clinical severity as a possible pre-
dictor for failing treatment at the community level [6].
Concurrent diagnosis and medication
Children with a concurrent diagnosis were less likely to
be adherent to oral antibiotics. In this study, a large pro-
portion of children had malaria as a secondary diagnosis,
yet concurrent malaria alone does not appear to be the
reason for non-adherence. Due to a lack of evidence sur-
rounding this topic, we speculate about possible reasons.
It is possible that once the child recovered from the con-
current disease, their symptoms were much better and
therefore the caregiver stopped giving the antibiotics. Al-
ternatively, as the course of medication for malaria and
many other diseases are shorter than 5 days, all medica-
tions may have been stopped together. Where a care-
giver receives instructions for treatment of multiple
conditions, confusion and lack of understanding could
result in errors following the correct prescription. It
would be expected that concurrent medications and
concurrent diagnosis would have almost 100% correl-
ation, yet this was not the case. Although moderate cor-
relation existed, the relationship was not as strong as
expected (correlation = 0.50). This could be attributed to
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mentation of the iCCM guidelines by CHWs.
At the time of this study, CHWs in Malawi were not
using rapid diagnostic testing for malaria. It is well docu-
mented that over-prescription of medication, particularly
in non-confirmed malaria, is a common problem in sub-
Saharan Africa [24]. It is also recognised that where
rapid malaria tests are available, there is a reduction in
prescription of malaria medication [25]. A limitation of
this work is that human immunodeficiency virus (HIV)
status of children was not collected due to practical and
ethical considerations because pediatric HIV testing was
not widely performed by government-sector CHWs in
Malawi at the time of this study [6]. Co-trimoxazole is
used as a prophylactic drug in children with HIV. HIV
prevalence is approximately 8% amongst adults, and
therefore a substantial percentage of these children
could already be taking co-trimoxazole [26]. Beliefs
about the drug itself, which parents could associate with
a diagnosis of HIV, may affect adherence.
Duration of illness
Children whose caregivers reported that they had symp-
toms for more than 24 h were less likely to complete the
course of antibiotics. We are not aware of any other com-
parable literature. Caregivers who took longer to present
their unwell child to clinic may have experienced more
problems with accessing the clinic, or may have a lower
socioeconomic status with limited ability to ensure chil-
dren took the medication. Similarly, a caregiver’s health
beliefs may influence the length of time taken to present
to the clinic or result in a perception their child was not as
sick. These reasons have been shown to increase non-
adherence in other conditions and could be causes of non-
adherence in those who have been unwell for longer [13].
Age
Older age was associated with improved adherence when
measured at 80%, but not 100%. Co-trimoxazole prescribed
in Malawi is a tablet that has to be split and crushed for
young children. Evidence suggests that ‘patient friendly’
medication tends to improve adherence, particularly taste
and texture with children [11]. Giving crushed tablets to a
young baby is potentially not ‘patient friendly’ and diffi-
cult for the caregiver. Similar results have been seen
in other studies, and suggest that alternative treat-
ment types (e.g. syrups or dispersible tablets) should
be investigated for improved adherence [13].
Treatment failure and non-adherence
This study was not powered to determine if non-
adherence was statistically associated to treatment fail-
ure. The slight increase in treatment failure in those who
were non-adherent needs further investigation with anappropriately powered study. Furthermore the limitation of
WHO guidelines should be taken into account, since infec-
tions treated with antibiotics in this study may have been
viral and thus reasonably be expected to have improved by
day 5 or 14 without treatment. There is a potential tension
when refining guidelines between encouraging non-specific
antibiotic prescription for possible bacterial infections
(where adherence will be beneficial and shorter-term mor-
tality benefits will be maximized) and reducing unnecessary
antibiotic use for self-resolving viral infections largely re-
sponsible for the development of increasing antimicrobial
resistance rates, a longer term public health concern.
Limitations
This study was limited by the lack of socioeconomic data,
with further research needed on the drivers of non-
adherence from a socioeconomic and behavioural stand
point. Records of a concurrent diagnosis and medication
and duration of illness were from caregiver reports, where
answers could be influenced by a range of socioeconomic
and social desirability issues, which could lead to both
over- and under-reporting. Measuring adherence by pill
count assumes that the child swallowed the tablets that
are not left, but it is possible they were thrown away, mis-
placed or lost, or sold. Over-reporting of adherence is
therefore possible when using pill count as the measure
[19]. Caution should also be given to the clinical measure-
ment used in this study, there is consistent evidence that
even with monthly supportive supervision and annual re-
fresher trainings, that accurate assessment of clinical signs
is poor in the community in Malawi [27, 28]. This is a sig-
nificant limitation of establishing clinical severity effects
on non-adherence within a community setting.
Conclusions
This analysis suggests that non-adherence to oral antibi-
otics is an issue in children diagnosed with community
treated iCCM pneumonia in Malawi. Although different
clinical severity (mild–moderate) at diagnosis is not as-
sociated with adherence, concurrent diagnoses, treat-
ments and duration of illness could be important factors
in driving treatment decisions and behaviour. Treatment
failure was higher in non-adherent children, despite not
demonstrating a statistically significant association, and
therefore improving adherence is a potential area for im-
proved community case management of pneumonia. As
multiple diagnoses and treatments were highlighted as
risks for poor adherence, refined diagnosis and treat-
ment pathways in these potentially clinically complex
children needs more investigation. Further research is
required into the drivers of treatment decisions by care-
givers and CHWs for acute infections in a sub-Saharan
African community setting to inform this process, and
to fill a considerable evidence gap.
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80% adherence 100% adherence
Adherent Non-adherent OR p-value 95% CI Adherent Non-adherent OR p-value 95% CI
Fevera Normal 493 45 432 106
High 234 31 1.45 0.129 0.89, 2.36 208 57 1.12 0.549 0.78, 1.60
Oxygen Saturationb Normal 643 66 566 134
Abnormal 113 13 1.11 0.754 0.59, 2.07 93 33 1.50 0.070 0.96, 2.33
Respiratory Ratec High 680 75 599 156
V.High 40 3 0.68 0.526 0.21, 2.25 35 8 0.88 0.745 0.40, 1.93
Heart Rated Normal 541 60 477 112
High 182 16 0.79 0.429 0.45, 1.41 162 48 1.26 0.232 0.86, 1.85
Clinical Malaria No 453 36 408 81
Yes 302 43 1.79 0.013 1.12, 2.86 259 86 1.67 0.003 1.19, 2.36
Diarrhoea No 733 73 648 158
Yes 22 6 2.74 0.028 1.07, 6.99 19 9 1.94 0.103 0.86, 4.38
Any Concurrent Diagnosis No 397 26 361 62
Yes 358 53 2.26 0.001 1.38, 9.71 306 105 2.00 0.001 1.40, 2.82
LAe No 377 27 340 64
Yes 378 52 1.92 0.008 1.80, 3.13 327 103 1.67 0.004 1.18, 2.37
Paracetamol No 381 23 342 62
Yes 374 56 2.48 0.001 1.49, 4.13 325 105 1.78 0.001 1.25, 2.53
Multiple Drugs No 300 19 269 50
Yes 455 60 2.08 0.006 1.21, 3.57 398 117 1.58 0.013 1.10, 2.28
Duration of illness <24h 450 32 408 74
>24h 301 46 2.15 0.001 1.33, 3.46 255 92 1.99 0.001 1.41, 2.82
Vomited after antibiotics No 658 68 581 145
Yes 96 10 1.01 0.982 0.50, 2.03 85 21 0.99 0.969 0.59, 1.65
Age 2–11mths 233 35 213 55
12–23mths 247 26 0.70 0.195 0.41, 1.20 210 63 1.16 0.472 0.77, 1.75
24–59mths 275 18 0.44 0.006 0.24, 0.79 244 49 0.79 0.248 0.52, 1.21
Sex Male 355 36 311 80
Female 386 43 0.91 0.693 0.57, 1.45 342 87 1.01 0.949 0.72, 1.42
aNormal: <=37.4 °C, High: > 37.4 °C ; bNormal: = > 95% Abnormal: <= 94%; cHigh: 40–59 (age 12–59 months) 50–69 (age 2–11 months), Very High: > = 60 (age
12–59 months) > =70 (age 2–11 months); dNormal: <159 (age 2–11months), <149 (age 12–23 months), <139 (age 24–59 months). LA: Lumefantrine Artemether
eLumefantrine Artemether prescribed by the community health workerAcknowledgements
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